An underground economy for unapproved weight-loss medications is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.
Experimental Drug Gaining Popularity Online
Retatrutide, which remains in research studies, is being promoted by social media influencers for its supposed weight-reducing properties. Followers are urged to message these accounts directly for supplier links, while also obtaining promotional offers.
Active Trade on Social Networks
Additionally, a robust trade exists on messaging services, where groups with numerous of members share “before and after” photos, injection guides and claims of next-day UK delivery. Sellers promote the drug there before redirecting customers to other platforms for purchases.
Understanding Retatrutide
This medication is an experimental injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help patients lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.
Healthcare Professionals Voice Concerns
Nevertheless, doctors and chemists have warned that the distribution of what is still an unlicensed medication in the United Kingdom is a cause for concern and could result in individuals injecting products of uncertain source.
Some experts stated the demand for the experimental drug could be linked to the rising price of approved slimming products such as Mounjaro.
Legal Position and Enforcement
Selling retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators attempt to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still breach medicines, advertising, and consumer laws, risking fines, legal action or prison.
Service Response and Material Removal
According to the social media company, the platform has removed problematic material and prohibited related hashtags and search suggestions. The company said it was committed to maintaining the platform safe and investing in strengthening compliance measures.
Digital Marketplace Activities
Research also found communities with up to nine thousand participants marketing retatrutide using Telegram's integrated search feature, which operates like a public directory. Typing “retatrutide” immediately displays channels with thousands of users, populated with images of slimming results, glowing reviews and step-by-step guides for preparing or injecting at home.
After minutes of joining one group, a vendor shared contact information, where most transactions take place. The vendor sent an instruction manual and promised delivery within 48 hours. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None asked about body mass, medical conditions or past usage.
Product Information and Costs
Within these groups, posts display black plastic parcels with postal service labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens typically sold at £160 for 20mg. When asked how long a injector should last, sellers give contradictory answers ranging from a several days to “depends on your body”.
Platform Oversight and Security Actions
A spokesperson for the messaging service said it regularly moderated dangerous material on its platform including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“Individuals are administering substances they cannot confirm. Even if the research behind retatrutide is valid, these online products may not include what they claim,” stated Jason Murphy, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of an online medical service connected the surge in demand to current price rises for approved slimming medications such as Mounjaro. “With costs rising, patients are turning to social media. But counterfeit treatments are extremely risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she said.
Her team has previously encountered patients injured by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.”
Manufacturer Statement
A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company investigational product not yet approved … may subject users to potentially significant health risks”.
